China's Medtech Regulatory Update Does Not Go Far Enough For Overseas Innovators
Law firm claims playing field is still far from level
Foreign medical device innovators accessing the Chinese market remain at a disadvantage to local companies, even after the recent regulatory pathway revision.
You may also be interested in...
China has amended its 2014 primary regulation governing medical devices. The new version of the Regulation on Supervision and Administration of Medical Devices comes into force on 1 June, says Todd Liao of Morgan Lewis.
A concerted effort to mobilize the pharma industry, research organizations and state-backed healthcare venture capital firms is under way in Shanghai.
Among other Asia deals, Takeda adds to pair of recent gene therapy tie-ups with a CNS-focused cell therapy partnership with Immusoft; earlier it licensed ex-US rights to JCR’s Hunter syndrome drug.